Background
In Europe, uveal melanoma (UM) is a rare disease (www.eurordis.org) annually affecting 2 to 8 Caucasians per million population -with an increasing incidence from southern to northern latitudes [1, 2] .
Despite radical ocular intervention(s),~50% of patients subsequently experience metastatic recurrence (mUM).
In the absence of effective therapeutic options, the reported median time-to-progression for patients with mUM is 2-3 months and median overall survival is 7-12 months [3] .
As a consequence of the rarity of the disease, there is significant variation in the treatment pathway [4] . Coupled with low survival, this results in sparse data on the disease burden of mUM to NHSE.
In 2015, the UK published their first national uveal melanoma guidelines [1] , which subsequently received accreditation from the National Institute for Health and Care Excellence (NICE).
Objectives
This study aimed to evaluate the patterns of care and medical resource use associated with a validated cohort of mUM patients identified within the Hospital Episodes Statistics (HES) database [5] . Medical procedures and tariff costs for NHSE inpatient, outpatient and Accident and Emergency (A&E) admissions were analysed. Clinical diagnoses were also available for inpatient admissions.
Following publication of the national guidelines [1], specialist care for UM patients is typically coordinated via 3 specialist supra-regional ocular oncological centres within England (London, Sheffield or Liverpool).
Due to data protection laws, hospital-specific data were unavailable. However, the city of treatment was accessible. Therefore, any inpatient treatment that occurred in London, Sheffield or Liverpool, was assumed to have occurred at a supra-regional ocular oncological centres.
To assess specific mUM resource utilisation, admissions prior to the index metastasis were omitted.
This analysis excluded costs not captured within HES (e.g. High Cost Drugs, Specialised Services, nonhospital palliative care).
Longitude and latitude for the patient's home city and treatment city were found using Google maps. The distance between home and treatment cities were calculated using the Haversine formula. All programming was completed in R (3.4.1 -R Foundation for Statistical Computing, Vienna, Austria).
Results
2,484 UM patients and 501 mUM patients were identified within HES and contributed inpatient data.
Data on outpatient and A&E visits were only available for a cohort of mUM patients assembled using an earlier version of the final mUM definition. Patients who were included in this earlier cohort and in the inpatient cohort could be considered in joint analyses of inpatient admissions and outpatient or A&E episodes. This condition was fulfilled for N = 462 UM patients and 383 mUM patients.
Conclusions
mUM was identified in~90% of our UM cohort whilst under surveillance at specialist centres.
Large variations in mUM medical resource utilisation were observed, reflecting the heterogeneity in: disease progression, local-regional care pathways and treatment effectiveness.
References & Acknowledgements Where patients receive care, before and after mUM diagnosis, shows a distinct difference and may be as a result of different treatment options being available, for different stages of disease.
Ocular-oncological surgery for primary UM and surveillance were mainly provided in the supra-regional centres, whereas hepatic surgery and systemic therapies (immunotherapy and chemotherapy) were also given in non-supra-regional centres.
Many outpatient visits occur in the data one month prior to mUM diagnosis. Unfortunately, diagnosis of mUM was only available within inpatient records. It may be possible that mUM was detected or treated in an outpatient setting prior to being recorded as an inpatient diagnosis. See Figures 2B & 3B to see this trend. 90% of all UM inpatients (n = 2,260) were treated at some point in a supra-regional centre area.
"Ophthalmology" was the most frequent speciality treating inpatients at the 1 st UM admission (91%) and at anytime whilst with a UM diagnosis (62% admissions).
43% of inpatients were treated >40 km from home.
43% of first inpatient admissions of metastatic disease (mUM) occurred in the supra-regional centre areas;
51% of all mUM inpatients (n = 258) were treated at some point in a supra-regional centre area.
"Oncology" was the most frequent (58%) treatment speciality treating inpatients at anytime whilst with a mUM diagnosis.
31% of inpatients were treated >40 km from home.
Over the observational period:
The total cost to NHSE for mUM inpatient admissions was £3.1 million (mean:£6,451/patient; range:£118-65,947) The cohort attended 5,056 outpatient appointments and had 899 A&E visits.
